Biotech

AntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement

MENLO PARK, CA: ...

Flamel Technologies Announces Resubmission of Second NDA

LYON, FRANCE: ...

Threshold Pharmaceuticals Announces Update on Its Phase 3 Trial in Soft Tissue Sarcoma

SOUTH SAN FRANCISCO, CA: Company to Host Conference Call and Webcast Today, July 1, 2013 at 8:30 AM ET ...

Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement

SAN DIEGO, CALIFORNIA and MONTREAL, CANADA: Mirati Therapeutics Begins Operations ...

GENEWIZ, Inc. and the John Theurer Cancer Center at Hackensack University Medical Center Announce Collaboration to Advance Ovarian Cancer Biomarker Discovery

SOUTH PLAINFIELD, NJ and HACKENSACK, NJ: ...

Warnex Announces the Re-Election of Directors and Status of Ongoing Strategic Review

LAVAL, QUEBEC: ...

Government of Canada and Partners Fund New Genomics Research Project to Eliminate Listeria From Food Supply

OTTAWA, ONTARIO: ...

Peregrine Pharmaceuticals Provides Update on Bavituximab Clinical Program

TUSTIN, CA: Company Strengthens Cash Position as It Prepares to Initiate Phase III Trial in Second-Line NSCLC by Year-End While Partnering Discussions Continue; Recent Data Supporting Novel Immunotherapy Mechanis ...

IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2013

MONTREAL, QUEBEC: ...

Portola to Initiate Phase 2 Study Evaluating the Safety and Effectiveness of Its Factor Xa Inhibitor Antidote PRT4445 in Reversing the Anticoagulant Activity of Investigational Factor Xa Inhibitor Edoxaban

SOUTH SAN FRANCISCO, CA: ...